A study led by Vedang Murthy, MD, at Tata Memorial Center, provided randomized evidence that adjuvant radiation can meaningfully reduce pelvic relapse after cystectomy for BladderCancer patients.
An abstract is unavailable.
Neurofilament light chain levels in cerebrospinal fluid and blood are higher in patients with behavioral variant frontotemporal dementia than psychiatric disorders, suggesting its potential as a biomarker to aid in differentiating these conditions.
This systematic review aimed to determine whether elevated CSF or blood NfL can aid clinicians in differentiating bvFTD from psychiatric disorders. Across 12 studies reviewed, CSF and blood NfL levels were consistently significantly higher in patients with bvFTD than patients with psychiatric disorders at the group level. Furthermore, CSF and blood NfL demonstrated reasonable sensitivity and specificity to differentiate bvFTD from psychiatric disorders,38 though classification accuracy varied somewhat by study. While some of the AUCs for NfL differentiating bvFTD from psychiatric disorders had wide confidence intervals, these findings suggest a possible role for NfL in diagnostic clarification of patients with neuropsychiatric presentations. Misdiagnosing bvFTD as a psychiatric disorder may delay patients with bvFTD from early access to clinical trials when treatments may be more effective. Conversely, misdiagnosing a psychiatric disorder as bvFTD may worsen quality of life and delay treatment of ameliorable conditions.39-41
The existing literature has important limitations. Most studies were case control in design since they enrolled patients meeting diagnostic criteria for bvFTD or psychiatric disorders and then examined the association of NfL with these diagnoses. While these studies are essential for determining construct validity, they are not representative of the real-world clinical conditions by which NfL would be used. Also, such methods risk biased interpretations of the relationship of NfL with these conditions. Further studies are needed that prospectively recruit patients with neuropsychiatric symptoms and obtain NfL using clinically available assays to aid in real-time differential diagnosis.
An additional limitation of the reviewed studies is the selection and heterogeneity of psychiatric disorders. Several of the reviewed studies included patients with primary substance use, adjustment, or functional neurological disorder diagnoses.27, 31, 32,34, 35 Mood disorders, schizophrenia, and OCD may have the greatest symptom overlap with bvFTD.42 However, only 5 studies reported enrolling a total of 9 patients with OCD,25, 29, 31, 35, 36 a condition with an estimated OR of onset of 4.9 among individuals aged 45 to 59 years,43 suggesting a need for studies that include more patients with psychiatric disorders more likely to mimic core features of bvFTD despite absence of suspected neurodegenerative pathology. Moreover, FTD phenocopy syndromes (phFTD), clinical features that mimic FTD of mid-to late-life onset but do not progress to dementia, are understudied.44 Only 1 study in this review included a total of 2 patients with phFTD.
Periodontitis is widespread and can have serious consequences for overall health. Researchers at Fraunhofer have identified a substance that selectively inhibits only those bacteria that cause periodontitis, thereby preserving the natural balance of the oral microbiome. This technology has been further developed and commercialized as a range of oral care products by the spin-off company PerioTrap.
The oral microbiome is home to more than 700 different bacterial species, of which only a few can cause periodontitis. These adhere to dental plaque, particularly along the gum line, where they trigger inflammation (gingivitis). This can potentially lead to chronic periodontitis, which does more than just cause receding gums and loose teeth. If these bacteria enter the bloodstream, they can also contribute to the development of diabetes, rheumatic disease, arthritis, cardiovascular disease, chronic inflammatory bowel disease and even Alzheimer’s disease.
Pathogenic bacteria are killed by conventional oral care products such as alcohol-based mouthwashes and products containing the antiseptic chlorhexidine, but these also eliminate beneficial microorganisms. When the oral microbiome re-establishes itself after treatment, pathogenic bacteria such as Porphyromonas gingivalis gain an early advantage because they proliferate particularly well in inflamed gum tissue. Beneficial bacteria grow more slowly, and the oral microbiome quickly shifts back from its natural balance into dysbiosis, allowing the disease to recur.
For the first time, researchers at UBC have demonstrated how to reliably produce an important type of human immune cell — known as helper T cells — from stem cells in a controlled laboratory setting. The findings, published today in Cell Stem Cell, overcome a major hurdle that has limited the development, affordability and large-scale manufacturing of cell therapies. The discovery could pave the way for more accessible and effective off-the-shelf treatments for a wide range of conditions like cancer, infectious diseases, autoimmune disorders and more.
“This is a major step forward in our ability to develop scalable and affordable immune cell therapies.”
Dr. Peter Zandstra
Ranked among the world’s top medical schools with the fifth-largest MD enrollment in North America, the UBC Faculty of Medicine is a leader in both the science and the practice of medicine. Across British Columbia, more than 12,000 faculty and staff are training the next generation of doctors and health care professionals, making remarkable discoveries, and helping to create the pathways to better health for our communities at home and around the world.
A research team at the Helmholtz-Zentrum Dresden-Rossendorf (HZDR) has developed a radiopharmaceutical molecule marker that can visualize tumors that carry the cell surface protein Nectin-4. This primarily occurs in the body in cases of urothelial carcinoma, a common form of bladder cancer.
In pre-clinical trials, the drug candidate, NECT-224, proved stable and was successfully used in humans for the first time. As the team has now reported in the Journal of Medicinal Chemistry, in the future, it could be used to better identify patients who would benefit from Nectin-4-targeted therapies.
Many modern cancer drugs only work when the target structure to which they are supposed to bind is also present on the tumor cells. In the case of urothelial carcinoma, the cell surface protein Nectin-4 lends itself to this purpose. It serves as a “door sign” for antibody-coupled agents that are able to eliminate tumor cells in a targeted fashion. But not every tumor produces the same amount of Nectin-4.
Glassy materials are everywhere, with applications far exceeding windowpanes and drinking glasses. They range from bioactive glasses for bone repair and amorphous pharmaceuticals that boost drug solubility to ultra-pure silica optics used in gravitational-wave detectors. In principle, any substance can become glass if its hot liquid is cooled fast enough to avoid forming an ordered crystal.
A distinguishing feature of glass is that its atoms freeze into an irregular, disordered arrangement. This stands in contrast to crystals, where atoms sit in a regular pattern. This disorder gives glass many of its unique and useful properties, but scientists still struggle to understand how atomic-scale disorder produces the properties observed in everyday glasses.
Most of us know the feeling: maybe it is making a difficult phone call, starting a report you fear will be criticized, or preparing a presentation that’s stressful just to think about. You understand what needs to be done, yet taking that very first step feels surprisingly hard.
When this difficulty becomes severe, it is known medically as avolition. People with avolition are not lazy or unaware: they know what they need to do, but their brain seems unable to push the “go” button.
Avolition is commonly seen in conditions such as depression, schizophrenia, and Parkinson’s disease, and it seriously disrupts a person’s ability to manage daily life and maintain social functions.
An analysis of genetic data from over 900,000 people shows that certain stretches of DNA, made up of short sequences repeated over and over, become longer and more unstable as we age. The study found that common genetic variants can speed up or slow down this process by up to four-fold, and that certain expanded sequences are linked to serious diseases including kidney failure and liver disease.
More than 60 inherited disorders are caused by expanded DNA repeats: repetitive genetic sequences that grow longer over time. These include devastating conditions like Huntington’s disease, myotonic dystrophy, and certain forms of ALS.
Most people carry DNA repeats that gradually expand throughout their lives, but this instability and what genetic factors control it hadn’t been fully analyzed within large biobanks.
In adults receiving cochlear implants, gains in positive affect and reductions in negative affect corresponded with improvements in quality-of-life scores across listening, communication, and participation domains. Strongest statistical associations were observed in social and emotional CIQOL areas, but effect sizes were small.
Importance The use of patient-reported outcome measures to assess outcomes in adults who use cochlear implants has increased, as highlighted by the inclusion of the Cochlear Implant Quality of Life (CIQOL) instruments in the Minimal Speech Testing Battery, version 3. However, the self-reported nature of these instruments raises questions regarding how psychosocial characteristics impact responses.
Objective To assess whether affect and CIQOL domain scores change over time and whether affect is associated with CIQOL domain scores.
Design, Setting, and Participants Prospective longitudinal cohort study in adult cochlear implant candidates (aged 18–89 years) meeting indications for cochlear implantation based on bilateral moderate to profound hearing loss with aided sentence recognition scores 60% or less between September 19, 2019, and October 8, 2021, in a single tertiary otolaryngology referral center. Patients receiving a second cochlear implant and those without Montreal Cognitive Assessment scores were excluded. Follow-up duration was 1 year. Data analysis was performed between October 15, 2023, and August 5, 2025.